Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial

AIMS: To evaluate the efficacy and safety of iGlarLixi compared with iGlar in Chinese adults with type 2 diabetes advancing therapy from basal insulin ± oral antihyperglycaemic drugs. MATERIALS AND METHODS: LixiLan‐L‐CN (NCT03798080) was a 30‐week randomized, active‐controlled, open‐label, parallel‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Xiaoyong, Guo, Xiaohui, Zhang, Junqing, Dong, Xiaolin, Lu, Yibing, Pang, Wuyan, Gu, Shenghong, Niemoeller, Elisabeth, Ping, Lin, Nian, Gaowei, Souhami, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795930/
https://www.ncbi.nlm.nih.gov/pubmed/35762489
http://dx.doi.org/10.1111/dom.14803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795930/
https://www.ncbi.nlm.nih.gov/pubmed/35762489
http://dx.doi.org/10.1111/dom.14803

Ejemplares similares